Nicole Stancel, Ph.D., ELS, of Scientific Publications at the Texas Heart Institute, provided editorial support. We also thank the following funding sources: the American Heart Association&#39;s National Center Scientist Development Grant (14SDG19840000 to J. Wang), the 2014 Lawrence Research Award from the Rolanette and Berdon Lawrence Bone Disease Program of Texas (to J. Wang), and the National Institutes of Health (DE026561 and DE025873 to J. Wang, DE016320 and DE019650 to R. Maxson).

1. Preparation Before O9-1 Cell Culture
NOTE: Basal media used for O9-1 cell culture must have been conditioned by Sandos inbred mice thioguanine/ouabain-resistant (STO) mouse fibroblast cells; therefore, STO cells need to be obtained and prepared as described below before starting O9-1 cell culture.
<ol>
	<li>Active STO cell culture
	<ol>
		<li>Prepare media for culturing active STO cells by making complete Dulbecco&#39;s modified Eagle&#39;s media (DMEM) with 7% fetal bovi...

<ol>
	<li>Achilleos, A., Trainor, P. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Neural+crest+stem+cells:+discovery,+properties+and+potential+for+therapy.">Neural crest stem cells: discovery, properties and potential for therapy.</a> Cell Research. 22 (2), 288-304 (2012).</li><li>Le Douarin, N. M., Dupin, E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Multipotentiality+of+the+neural+crest.">Multipotentiality of the neural crest.</a> Current Opinion in Genetics and Development. 13 (5), 529-536 (2003).</li><li>Santagati, F., Rijli, F. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Cranial+neural+crest+and+the+building+of+the+vertebrate+head.">Cranial neural crest and the building of the vertebrate head.</a> Nature Reviews. Neuroscience. 4 (10), 806-818 (2003).</li><li>Cordero, D. R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Cranial+neural+crest+cells+on+the+move:+their+roles+in+craniofacial+development.">Cranial neural crest cells on the move: their roles in craniofacial development.</a> American Journal of Medical Genetics. Part A. 155 (2), 270-279 (2011).</li><li>Trainor, P. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Craniofacial+birth+defects:+The+role+of+neural+crest+cells+in+the+etiology+and+pathogenesis+of+Treacher+Collins+syndrome+and+the+potential+for+prevention.">Craniofacial birth defects: The role of neural crest cells in the etiology and pathogenesis of Treacher Collins syndrome and the potential for prevention.</a> American Journal of Medical Genetics. Part A. 152 (12), 2984-2994 (2010).</li><li>Bronner, M. E., Simoes-Costa, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+neural+crest+migrating+into+the+twenty-first+century.">The neural crest migrating into the twenty-first century.</a> Current Topics in Developmental Biology. , 115-134 (2016).</li><li>Zurkirchen, L., Sommer, L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Quo+vadis:+tracing+the+fate+of+neural+crest+cells.">Quo vadis: tracing the fate of neural crest cells.</a> Current Opinion in Neurobiology. 47, 16-23 (2017).</li><li>Sauka-Spengler, T., Bronner-Fraser, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+gene+regulatory+network+orchestrates+neural+crest+formation.">A gene regulatory network orchestrates neural crest formation.</a> Nature Reviews. Molecular Cell Biology. 9 (7), 557-568 (2008).</li><li>Knecht, A. K., Bronner-Fraser, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Induction+of+the+neural+crest:+a+multigene+process.">Induction of the neural crest: a multigene process.</a> Nature Reviews. Genetics. 3 (6), 453-461 (2002).</li><li>Steventon, B., Carmona-Fontaine, C., Mayor, R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Genetic+network+during+neural+crest+induction:+from+cell+specification+to+cell+survival.">Genetic network during neural crest induction: from cell specification to cell survival.</a> Seminars in Cell and Developmental Biology. 16 (6), 647-654 (2005).</li><li>Raible, D. W. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Development+of+the+neural+crest:+achieving+specificity+in+regulatory+pathways.">Development of the neural crest: achieving specificity in regulatory pathways.</a> Current Opinion in Cell Biology. 18 (6), 698-703 (2006).</li><li>Dupin, E., Sommer, L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Neural+crest+progenitors+and+stem+cells:+from+early+development+to+adulthood.">Neural crest progenitors and stem cells: from early development to adulthood.</a> Developmental Biology. 366 (1), 83-95 (2012).</li><li>Henion, P. D., Weston, J. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Timing+and+pattern+of+cell+fate+restrictions+in+the+neural+crest+lineage.">Timing and pattern of cell fate restrictions in the neural crest lineage.</a> Development. 124 (21), 4351-4359 (1997).</li><li>Harris, M. L., Erickson, C. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Lineage+specification+in+neural+crest+cell+pathfinding.">Lineage specification in neural crest cell pathfinding.</a> Developmental Dynamics. 236 (1), 1-19 (2007).</li><li>Luo, R., Gao, J., Wehrle-Haller, B., Henion, P. D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Molecular+identification+of+distinct+neurogenic+and+melanogenic+neural+crest+sublineages.">Molecular identification of distinct neurogenic and melanogenic neural crest sublineages.</a> Development. 130 (2), 321-330 (2003).</li><li>Betters, E., Liu, Y., Kjaeldgaard, A., Sundstrom, E., Garcia-Castro, M. I. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Analysis+of+early+human+neural+crest+development.">Analysis of early human neural crest development.</a> Developmental Biology. 344 (2), 578-592 (2010).</li><li>Yang, S. Y., Beavan, M., Chau, K. Y., Taanman, J. W., Schapira, A. H. V. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+human+neural+crest+stem+cell-derived+dopaminergic+neuronal+model+recapitulates+biochemical+abnormalities+in+GBA1+mutation+carriers.">A human neural crest stem cell-derived dopaminergic neuronal model recapitulates biochemical abnormalities in GBA1 mutation carriers.</a> Stem Cell Reports. 8 (3), 728-742 (2017).</li><li>Ishii, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+stable+cranial+neural+crest+cell+line+from+mouse.">A stable cranial neural crest cell line from mouse.</a> Stem Cells and Development. 21 (17), 3069-3080 (2012).</li><li>Yumoto, K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=TGF-beta-activated+kinase+1+(Tak1)+mediates+agonist-induced+Smad+activation+and+linker+region+phosphorylation+in+embryonic+craniofacial+neural+crest-derived+cells.">TGF-beta-activated kinase 1 (Tak1) mediates agonist-induced Smad activation and linker region phosphorylation in embryonic craniofacial neural crest-derived cells.</a> Journal of Biological Chemistry. 288 (19), 13467-13480 (2013).</li><li>Wang, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Yap+and+Taz+play+a+crucial+role+in+neural+crest-derived+craniofacial+development.">Yap and Taz play a crucial role in neural crest-derived craniofacial development.</a> Development. 143 (3), 504-515 (2016).</li><li>Heallen, T., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Hippo+pathway+inhibits+Wnt+signaling+to+restrain+cardiomyocyte+proliferation+and+heart+size.">Hippo pathway inhibits Wnt signaling to restrain cardiomyocyte proliferation and heart size.</a> Science. 332 (6028), 458-461 (2011).</li><li>Wang, J., Martin, J. F. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Hippo+pathway:+An+emerging+regulator+of+craniofacial+and+dental+development.">Hippo pathway: An emerging regulator of craniofacial and dental development.</a> Journal of Dental Research. 96 (11), 1229-1237 (2017).</li><li>Pan, D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+hippo+signaling+pathway+in+development+and+cancer.">The hippo signaling pathway in development and cancer.</a> Developmental Cell. 19 (4), 491-505 (2010).</li><li>Xiao, Y., Leach, J., Wang, J., Martin, J. F. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Hippo/Yap+signaling+in+cardiac+development+and+regeneration.">Hippo/Yap signaling in cardiac development and regeneration.</a> Current Treatment Options in Cardiovascular Medicine. 18 (6), 38 (2016).</li><li>Yu, F. X., Meng, Z., Plouffe, S. W., Guan, K. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Hippo+pathway+regulation+of+gastrointestinal+tissues.">Hippo pathway regulation of gastrointestinal tissues.</a> Annual Review of Physiology. 77, 201-227 (2015).</li><li>Fu, V., Plouffe, S. W., Guan, K. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+Hippo+pathway+in+organ+development,+homeostasis,+and+regeneration.">The Hippo pathway in organ development, homeostasis, and regeneration.</a> Current Opinion in Cell Biology. 49, 99-107 (2017).</li><li>Moya, I. M., Halder, G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+Hippo+pathway+in+cellular+reprogramming+and+regeneration+of+different+organs.">The Hippo pathway in cellular reprogramming and regeneration of different organs.</a> Current Opinion in Cell Biology. 43, 62-68 (2016).</li><li>Piccolo, S., Dupont, S., Cordenonsi, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+biology+of+YAP/TAZ:+hippo+signaling+and+beyond.">The biology of YAP/TAZ: hippo signaling and beyond.</a> Physiological Reviews. 94 (4), 1287-1312 (2014).</li><li>Bauer, D. E., Canver, M. C., Orkin, S. H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Generation+of+genomic+deletions+in+mammalian+cell+lines+via+CRISPR/Cas9.">Generation of genomic deletions in mammalian cell lines via CRISPR/Cas9.</a> Journal of Visual Experiments : JoVE. (95), e52118 (2015).</li><li>Ran, F. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Genome+engineering+using+the+CRISPR-Cas9+system.">Genome engineering using the CRISPR-Cas9 system.</a> Nature Protocols. 8 (11), 2281-2308 (2013).</li><li>Manderfield, L. J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Hippo+signaling+is+required+for+Notch-dependent+smooth+muscle+differentiation+of+neural+crest.">Hippo signaling is required for Notch-dependent smooth muscle differentiation of neural crest.</a> Development. 142 (17), 2962-2971 (2015).</li><li>Hindley, C. J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+Hippo+pathway+member+YAP+enhances+human+neural+crest+cell+fate+and+migration.">The Hippo pathway member YAP enhances human neural crest cell fate and migration.</a> Scientific Reports. 6, 23208 (2016).</li><li>Nejigane, S., Haramoto, Y., Okuno, M., Takahashi, S., Asashima, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+transcriptional+coactivators+Yap+and+TAZ+are+expressed+during+early+Xenopus+development.">The transcriptional coactivators Yap and TAZ are expressed during early Xenopus development.</a> International Journal of Developmental Biology. 55 (1), 121-126 (2011).</li><li>Grefte, S., Vullinghs, S., Kuijpers-Jagtman, A. M., Torensma, R., Von den Hoff, J. W. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Matrigel,+but+not+collagen+I,+maintains+the+differentiation+capacity+of+muscle+derived+cells+in+vitro.">Matrigel, but not collagen I, maintains the differentiation capacity of muscle derived cells in vitro.</a> Biomedical Materials. 7 (5), 055004 (2012).</li><li>Kang, B. J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Effect+of+matrigel+on+the+osteogenic+potential+of+canine+adipose+tissue-derived+mesenchymal+stem+cells.">Effect of matrigel on the osteogenic potential of canine adipose tissue-derived mesenchymal stem cells.</a> Journal of Veterinary Medical Science. 74 (7), 827-836 (2012).</li><li>Uemura, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Matrigel+supports+survival+and+neuronal+differentiation+of+grafted+embryonic+stem+cell-derived+neural+precursor+cells.">Matrigel supports survival and neuronal differentiation of grafted embryonic stem cell-derived neural precursor cells.</a> Journal of Neuroscience Research. 88 (3), 542-551 (2010).</li></ol>

The NCC is a versatile and key contributor to different tissues and organs during embryonic morphogenesis.The O9-1 cell line maintains its potential to differentiate into many different cell types and mimics the in vivo characteristics of NCCs, making it a useful in vitro tool for studying gene function and molecular regulation in NCCs. The different status of O9-1 cells may correspond to different neural crest progeny in vivo, depending on the culture conditions of O9-1 cells. O9-1 cells can b...

An erratum was issued for: <a href="https://www.jove.com/video/58346/culturing-and-manipulation-of-o9-1-neural-crest-cells">Culturing and Manipulation of O9-1 Neural Crest Cells</a>. The Protocol section was updated.
Step 2.1 was updated from:
Prepare basal media for O9-1 cell culture by adding the following in DMEM (final concentrations are indicated): 15% FBS, 0.1 mM minimum essential media (MEM) nonessential amino acids, 1 mM sodium pyruvate, 55 mM beta-mercaptoethanol, 100 U/mL penicillin, 100 U/mL streptomycin, 2 mM L-glutamine, 103 units/mL leukemia inhibitory factor (LIF; added immediately before use, do not add to stock bottle), and 25 ng/mL fibroblast growth factor-basic (bFGF; added immediately before use, do not add to stock bottle).
to:
Prepare basal media for O9-1 cell culture by adding the following in DMEM (final concentrations are indicated): 15% FBS, 0.1 mM minimum essential media (MEM) nonessential amino acids, 1 mM sodium pyruvate, 55 &#181;M beta-mercaptoethanol, 100 U/mL penicillin, 100 &#181;g/mL streptomycin, 2 mM L-glutamine, 103 units/mL leukemia inhibitory factor (LIF; added immediately before use, do not add to stock bottle), and 25 ng/mL fibroblast growth factor-basic (bFGF; added immediately before use, do not add to stock bottle).
Step 5.1.1 was updated from:
To prepare osteogenic differentiation media, dilute the following in alpha-MEM (final concentrations are indicated): 0.1 mM dexamethasone, 100 ng/mL bone morphogenetic protein 2 (BMP2), 50 &#181;g/mL ascorbic acid, 10 mM b-glycerophosphate, 10% FBS, 100 U/mL penicillin, and 100 mg/mL streptomycin.
to:
To prepare osteogenic differentiation media, dilute the following in alpha-MEM (final concentrations are indicated): 0.1 &#181;M dexamethasone, 100 ng/mL bone morphogenetic protein 2 (BMP2), 50 &#181;g/mL ascorbic acid, 10 mM b-glycerophosphate, 10% FBS, 100 U/mL penicillin, and 100 &#181;g/mL streptomycin.
Step 5.2.1 was updated from:
To prepare chondrocyte differentiation media, dilute the following in alpha-MEM (final concentrations are indicated): 5% fetal calf serum (FCS), 1% insulin-transferrin-selenium (ITS), 100 U/mL penicillin, 100 mg/mL streptomycin, 10 ng/mL transforming growth factor beta (TGF-b3), 50 mg/mL ascorbic acid, 10 ng/mL BMP2, 0.1 mM dexamethasone, and 1 mM sodium pyruvate.
to:
To prepare chondrocyte differentiation media, dilute the following in alpha-MEM (final concentrations are indicated): 5% fetal calf serum (FCS), 1% insulin-transferrin-selenium (ITS), 100 U/mL penicillin, 100 &#181;g/mL streptomycin, 10 ng/mL transforming growth factor beta (TGF-b3), 50 &#181;g/mL ascorbic acid, 10 ng/mL BMP2, 0.1 &#181;M dexamethasone, and 1 mM sodium pyruvate.
Step 5.4.1 was updated from:
To prepare glial cell differentiation media, dilute the following in DMEM/F12 (final concentrations are indicated): 1x B-27 supplement, 2 mM L-glutamine, 50 ng/mL BMP2, 100 U/mL penicillin, 100 mg/mL streptomycin, 50 ng/mL LIF, and 1% heat-inactivated FBS.
to:
To prepare glial cell differentiation media, dilute the following in DMEM/F12 (final concentrations are indicated): 1x B-27 supplement, 2 mM L-glutamine, 50 ng/mL BMP2, 100 U/mL penicillin, 100 &#181;g/mL streptomycin, 50 ng/mL LIF, and 1% heat-inactivated FBS.

An erratum was issued for: <a href="https://www.jove.com/video/58346/culturing-and-manipulation-of-o9-1-neural-crest-cells">Culturing and Manipulation of O9-1 Neural Crest Cells</a>. The Protocol section was updated.

Erratum: Culturing and Manipulation of O9-1 Neural Crest Cells

Neural crest cells (NCCs) are multipotent stem-like cells with a remarkable migratory ability and transient existence during embryonic development. NCCs originate between the surface ectoderm and the neural tube and migrate to other parts of the embryo during embryonic development1. Based on their functional domains, NCCs can be classified into several different types, including cranial, trunk, vagal, sacral, and cardiac NCCs. In addition, NCCs can differentiate into multiple cell lineages, such as smooth muscle cells, bone cells, and neurons, and give rise to various tissues2,3. The development of NCCs is characterized by a complex series of morphogenetic events that are fine-tuned by various molecular signals. Given the complex regulation of NCCs and their important contributions to numerous structures, the dysregulation of NCC development can commonly lead to congenital birth defects, which account for nearly 30% of all human congenital birth defects. Abnormalities during the neural crest development can lead to cleft lip/palate, flawed nose formation, syndromes, defects such as a defective cardiac outflow tract, or even infant mortality1,4,5,6,7. Understanding the molecular mechanisms of NCC development is important for developing treatments for diseases caused by defects in NCC development. With the use of various in vitro and in vivo approaches8,9,10,11,12,13,14,15, considerable progress has been made in NCC research. In vivo, animal models, including chickens, amphibians, zebrafish, and mice, have been used to investigate NCCs1. Furthermore, human embryos have been used to study the process of NCC migration in early human embryo development16. In vitro, cell models for NCCs, such as human NCCs that originated from patient subcutaneous fat, have been used to investigate Parkinson&#39;s disease17. The O9-1 NCC line, which was originally derived from mass cultures of endogenous NCCs isolated from E8.5 mouse embryos18, is a powerful cell model for studying NCCs. Importantly, under non-differentiating culture conditions, O9-1 cells are multipotent stem-like NCCs. However, under varying culture conditions, O9-1 cells can be differentiated into distinguished cell types, such as smooth muscle cells, osteoblasts, chondrocytes, and glial cells18. Given these properties, O9-1 cells have been broadly used for NCC-related studies, such as investigating the molecular mechanism of cranial-facial defects19,20.
Here, detailed protocols are provided for maintaining O9-1 cells, differentiating O9-1 cells into different cell types, and manipulating O9-1 cells by performing gene loss-of-function studies with CRISPR-Cas9 genome editing and small interfering RNA (siRNA)-mediated knockdown technologies. As a representative example, the use of O9-1 cells to study Yap and Taz loss-of-function is described. Yap and Taz are the downstream effectors of the Hippo signaling pathway, which plays a critical role in the cell proliferation, differentiation, and apoptosis. The Hippo pathway has also been shown to be important in the development and homeostasis of several different tissues and organs, as well as in the pathogenesis of different diseases20,21,22,23,24,25,26,27,28. The core components of Hippo signaling include the tumor suppressor sterile 20-like kinases Mst1/2, WW domain-containing Salvador scaffold protein, and the large tumor suppressor homolog (Lats1/2) kinases. Hippo signaling inhibits Yap and Taz activity and promotes their degradation in the cytoplasm. Without repression from Hippo, Yap and Taz can translocate into nuclei and function as transcriptional co-activators. We recently showed that specifically inactivating the Hippo signaling effectors Yap and Taz in mouse NCCs by using the Wnt1cre and Wnt1Cre2SOR drivers resulted in embryonic lethality at E10.5 with severe craniofacial defects20. We have also performed studies using O9-1 cells to investigate the role of Yap and Taz in NCCs. To study Yap and Taz function in NCC proliferation and differentiation, Yap and Taz knockdown cells were generated in O9-1 cells by using siRNA, and Yap knockout cells were generated by using CRISPR-Cas9 genome editing. The same gene loss-of-function strategies can be applied to different target genes in other pathways. In addition, gain-of-function studies and transfection assays can also be applied to O9-1 cells to study gene function and regulation. The protocols described here are intended to be used by investigators as guides for culturing O9-1 cells to maintain multipotent stemness, for differentiating O9-1 cells into other cell types under different culture conditions, and for studying gene function and the molecular mechanisms of NCCs.

<table>
	<tbody>
		<tr>
			<td>Active STO feeder cells</td>
			<td>ATCC</td>
			<td>ATCC CRL-1503</td>
			<td>Also available in mitomycin C-inactivated form, catalog # ATCC 56-X</td>
		</tr>
		<tr>
			<td>O9-1 mouse cranial neural crest cell line</td>
			<td>Millipore Sigma</td>
			<td>SCC049</td>
			<td></td>
		</tr>
		<tr>
			<td>DMEM, high glucose, no glutamine</td>
			<td>Gibco</td>
			<td>11960-044</td>
			<td></td>
		</tr>
		<tr>
			<td>DMEM, high glucose</td>
			<td>Hyclone</td>
			<td>SH30243.01</td>
			<td></td>
		</tr>
		<tr>
			<td>FBS (fetal bovine serum)</td>
			<td>Millipore Sigma</td>
			<td>ES-009-B</td>
			<td></td>
		</tr>
		<tr>
			<td>Penicillin - streptomycin</td>
			<td>Gibco</td>
			<td>15140-122</td>
			<td></td>
		</tr>
		<tr>
			<td>L-glutamine 200mM (100X)</td>
			<td>Gibco</td>
			<td>25030-081</td>
			<td></td>
		</tr>
		<tr>
			<td>Gelatin from porcine skin</td>
			<td>Sigma</td>
			<td>G1890</td>
			<td></td>
		</tr>
		<tr>
			<td>Trypsin-EDTA 0.25% in HBSS</td>
			<td>Genesee Scientific</td>
			<td>25-510</td>
			<td></td>
		</tr>
		<tr>
			<td>DPBS (Dulbecco&#39;s phosphate buffered saline) without calcium or magnesium</td>
			<td>Lonza</td>
			<td>17-512F</td>
			<td></td>
		</tr>
		<tr>
			<td>MEM non-essential amino acids (MEM NEAA) 100X</td>
			<td>Gibco</td>
			<td>11140-050</td>
			<td></td>
		</tr>
		<tr>
			<td>Sodium pyruvate (100mM)</td>
			<td>Gibco</td>
			<td>11360-070</td>
			<td></td>
		</tr>
		<tr>
			<td>2-Mercaptoethanol</td>
			<td>Sigma</td>
			<td>M-7522</td>
			<td></td>
		</tr>
		<tr>
			<td>ESGRO leukemia inhibitory factor (LIF) 106 unit/ml</td>
			<td>Millipore Sigma</td>
			<td>ESG1106</td>
			<td></td>
		</tr>
		<tr>
			<td>Recombinant human fibroblast growth factor-basic (rhFGF-basic)</td>
			<td>R&#38;D Systems</td>
			<td>233-FB-025</td>
			<td></td>
		</tr>
		<tr>
			<td>Mitomycin C</td>
			<td>Roche</td>
			<td>10107409001</td>
			<td></td>
		</tr>
		<tr>
			<td>Matrigel matrix</td>
			<td>Corning</td>
			<td>356234</td>
			<td></td>
		</tr>
		<tr>
			<td>DMSO (dimethylsulfoxide)</td>
			<td>Millipore Sigma</td>
			<td>MX1458-6</td>
			<td></td>
		</tr>
		<tr>
			<td>Lipofectamine RNAiMAX</td>
			<td>Thermo Fisher Scientific</td>
			<td>13778-075</td>
			<td></td>
		</tr>
		<tr>
			<td>Opti-MEM I (1X)</td>
			<td>Gibco</td>
			<td>31985-070</td>
			<td></td>
		</tr>
		<tr>
			<td>Minimum essential medium, alpha 1X with Earle&#39;s salts, ribonucleosides, deoxyribonucleosides, &#38; L-glutamine</td>
			<td>Corning</td>
			<td>10-022-CV</td>
			<td></td>
		</tr>
		<tr>
			<td>ON-TARGETplus Wwtr1 siRNA</td>
			<td>Dharmacon</td>
			<td>L-041057</td>
			<td></td>
		</tr>
		<tr>
			<td>ON-TARGETplus Non-targeting Pool</td>
			<td>Dharmacon</td>
			<td>D-001810</td>
			<td></td>
		</tr>
		<tr>
			<td>ON-TARGETplus Yap1 siRNA</td>
			<td>Dharmacon</td>
			<td>L-046247</td>
			<td></td>
		</tr>
		<tr>
			<td>FCS (fetal calf serum)</td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>ITS (insulin-transferrin-selenium )</td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>TGF-b3</td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>Ascorbic acid</td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>BMP2 (bone morphogenetic protein 2)</td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>Dexamethasone</td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>B-27 supplement</td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
	</tbody>
</table>

culturing and manipulation of o9-1 neural crest cells

Neural crest cells (NCCs) are migrating multipotent stem cells that can differentiate into different cell types and give rise to multiple tissues and organs. The O9-1 cell line is derived from the endogenous mouse embryonic NCCs and maintains its multipotency. However, under specific culture conditions, O9-1 cells can differentiate into different cell types and be utilized in a wide range of research applications. Recently, with the combination of mouse studies and O9-1 cell studies, we have shown that the Hippo signaling pathway effectors Yap and Taz play important roles in neural crest-derived craniofacial development. Although the culturing process for O9-1 cells is more complicated than that used for other cell lines, the O9-1 cell line is a powerful model for investigating NCCs in vitro. Here, we present a protocol for culturing the O9-1 cell line to maintain its stemness, as well as protocols for differentiating O9-1 cells into different cell types, such as smooth muscle cells and osteoblasts. In addition, protocols are described for performing gene loss-of-function studies in O9-1 cells by using CRISPR-Cas9 deletion and small interfering RNA-mediated knockdown.

The goal of our knockdown and knockout experiments was to study the effects of Yap and Taz loss-of-function in O9-1 cells. Before the knockdown and knockout experiments, we have to make sure that prepare for basal media and culture O9-1 cells as described above (for example, basement membrane matrix needs to cover the whole plate as shown in Figure 1, and O9-1 cells recovered from liquid nitrogen as shown in Figure 2</st...

Watch this Scientific Journal Video about Culturing and Manipulation of O9-1 Neural Crest Cells at JoVE.com

Culturing and Manipulation of O9-1 Neural Crest Cells

O9-1 is a multipotent mouse neural crest cell line. Here we describe detailed step-by-step protocols for culturing O9-1 cells, differentiating O9-1 cells into specific cell types, and genetically manipulating O9-1 cells by using siRNA-mediated knockdown or CRISPR-Cas9 genome editing.

Neural crest cells (NCCs) are migrating multipotent stem cells that can differentiate into different cell types and give rise to multiple tissues and ...

The O9-1 cell line is a very useful tool for studying neural crest cells in vitro. It has a great potential for use in a wide range of application in various use of research. O9-1 cells have obvious advantages, such as easy access, and quickly obtaining sufficient cell numbers for experiments, making it a powerful method complimentary to in vitro studies of neural crest cells.To begin, prepare basal media for O9-1 cell culture, according to the text protocol. Then, filter the basal media, and wrap it in foil to protect it from the light. After this, collect conditioned basal media from an activated STO cells according to the text protocol.First, thaw an aliquot of basement membrane matrix on ice for two hours. Then, dilute the basement membrane matrix with filtered sterilized DMEM with 10%FBS to a final concentration of 0.5mg/ml. Coat the plate with the basement membrane matrix at room temperature for one hour.Then, aspirate the basement membrane matrix while tilting the plate. Dry the plates at 30 degrees Celsius for 30 minutes. When adding the basement membrane matrix to the plate, make sure the solution covered the well evenly to maintain cell characteristics and avoid unnecessary variation in between experiments.Recover O9-1 cells by placing a cryo-vial into a 37 degree Celsius water-bath. Slowly swirl the vial until the solution completely turns to liquid. After this, transfer the cell solution from the cryo-vial to a 15ml centrifuge tube.Add five volumes of DMEM with 10%FBS to the tube to re-suspend the cells. Centrifuge the cells for three minutes at 180 Gs.Then, aspirate the supernatent, taking care not to disturb the pellet. Next, re-suspend the pellet in conditioned basal media supplemented with LIF and BFGF.Seed the cells in a six well plate, and agitate the plate to seed the cells evenly. When agitating the plate, do so horizontally and vertically, as swirling the plate will cause the cells to concentrate towards the center. And allow those cells to attach and grow in a standard cell culture incubator overnight.Ensure the cells are attached before changing the media. When the O9-1 cells reach 80%confluency, thaw the basement membrane matrix and prepare a basement membrane matrix coated plate as described previously. Then add basal media supplemented with LIF and BFGF to the membrane matrix.Gently rinse the wells with 2ml of DPBS twice. Then, dissociate the cells with 1ml of 0.05%trypsin EDTA at 37 degrees Celsius for three minutes. Neutralize the trypsin with an equal amount of DMEM with 10%FBS by repeatedly pipetting the liquid over the whole surface of the well.Then, transfer the cell solution to a centrifuge tube. And centrifuge for three minutes at 180 Gs.Aspirate the supernatent without disturbing the pellet of cells. Next, resuspend the cell pellet by gently pippetting conditioned basal media supplemented with LIF and BFGF.Seed the cells to the coated plate as previously described. Then, allow the cells to attach and grow in a standard cell culture incubator. First, prepare the 2X freezing media according to the text protocol.Then, filter-sterilize the media. Rinse the walls of the plate with DPBS twice, pipetting gently to avoid losing cells. Next dissociate the cells with 0.05%trypsin EDTA at 37 degrees Celsius for three minutes.Neutralize the trypsin with an equal amount of 10%FBS and DMEM. Transfer the contents of the plate to a centrifuge tube, and centrifuge for three minutes at 180 Gs.Then, aspirate the supernatent and add 2ml of PBS to resuspend the pellet. Centrifuge the cell solution once more and aspirate the supernatent.Adjust the amount of basal media in the tube as needed, and add an equal amount of 2X freezing media. Next, transfer the cells to the labeled cryo vials. Place the cryo vials inside a polystyrene box with a lid to achieve a slow cooling rate at 80 degrees Celsius for at least 24 hours.To perform SIRNA knockdown in O9-1 cells, recover and seed the cells. Dilute liposomes in an appropriate volume of serum-free media. Then, dilute SIRNA in serum-free media according to the text protocol.After this, add the diluted SIRNA to the diluted liposomes, according to the manufacturer's instructions. Mix the solution by pipetting, and incubate for five minutes at room temperature. Next, add an appropriate volume of SIRNA lipid complex to the cells.Then, incubate the cells for 24 hours in a standard cell culture incubator. O9-1 cells can differentiate into different cell types under specific differentiation culture conditions. To differentiate O9-1 cells into osteoplasts, prepare osteogenic differentiation media according to the text protocol.Finally, detect the osteoplast marker osteocalcin in differentiated osteoplasts by immuno staining. To differentiate O9-1 cells into smooth muscle cells, culture them under differentiation media according to the text protocol, and evaluate the differentiation by smooth-muscle actin immuno staining. In this protocol, both knock out and knock down experiment to study Yap loss of function in O9-1 cells were performed.Under smooth muscle cell differentiation conditions, most wild type O9-1 cells gave rise to smooth muscle actin positive smooth muscle cells. Yap null cells however generally failed to differentiate into SMA positive smooth muscle cells. This indicates that Yap plays a critical role in the differentiation of neural crest cells into smooth muscle cells.While attempting this procedure, it's important to remember to handle the O9-1 cell line gently and carefully during the entire process. Make sure to dilute and use the basal membrane matrix properly, and use 0.05%trypsin for cell dissociation. Don't forget that during the preparation for O9-1 cell culture, working with mitomycin c can be extremely hazardous, and precautions such as wearing a lab coat and gloves should always be taken while performing this procedure.

culturing-and-manipulation-of-o9-1-neural-crest-cells

Research

JoVE Journal

Genetics

9.5K visualizações.  Baylor College of Medicine. A linha celular O9-1 é uma ferramenta muito útil para estudar células de crista neural in vitro. Tem um grande potencial para uso em uma ampla gama de aplicações em vários usos de pesquisa. As células O9-1 têm vantagens óbvias, como fácil acesso, e rapidamente obtenção de números celulares suficientes para experimentos, tornando-se um método poderoso de cortesia a estudos in vitro de células de crista neural.Para começar, prepare a mídia basal para a cultura celular O9...